Replit has introduced Agent 3, its latest autonomous software agent built to extend the use of AI in programming and workflow ...

Investors are always looking for stocks that are poised to beat at earnings season and Replimune REPL may be one such company. The firm has earnings coming up pretty soon, and events are shaping up ...

Replimune stock dives 54% over three months after the FDA rejects its RP1/Opdivo melanoma drug filing, delaying its first potential product launch.

RP1 combined with Opdivo® (nivolumab) continues to demonstrate deep and durable responses in patients with melanoma and non-melanoma skin cancers (NMSC); new positive initial data in patients with ...

Replimune reviews FDA feedback on its RP1 advanced melanoma treatment application. Stay updated on next steps and biotech market impact.